Fighting the “Fire” of Myocardial Reperfusion Injury How to Define Success?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Wu, Katherine C.
F
M
H
K
B
I
g
p
c
n
t
b
r
r
r
t
t
m
c
s
s
d
i
T
t
i
e
a
t
t
a
u
i
w
m
i
s
a
m
f
e
t
c
t
fi
b
c
e
i
l
t
2
i
p
o
s
b
H
s
e
o
i
M
t
o
p
a
e
e
m
t
d
s
S
o
w
F
L
f
a
i
s
d
w
s
C
*
v
A
M
R
r
Journal of the American College of Cardiology Vol. 53, No. 8, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2009.01.002EDITORIAL COMMENT
ighting the “Fire” of
yocardial Reperfusion Injury
ow to Define Success?*
atherine C. Wu, MD, FACC
altimore, Maryland
t is axiomatic that after an acute myocardial infarction, the
reatest impact in limiting infarct size and improving
atient prognosis occurs with prompt reperfusion by me-
hanical or pharmacologic thrombolysis. However, as Jen-
ings et al. (1) originally observed, reperfusion itself poten-
ially exacerbates myocardial damage above that produced
y the initial ischemic insult in 2 irreversible ways: lethal
eperfusion injury and vascular reperfusion injury or no-
eflow (1–3). Lethal reperfusion injury arises when sudden
estoration of coronary flow causes necrosis of myocytes
hat, while injured by the antecedent ischemia, were poten-
ially salvageable at the time of reperfusion. Postulated
echanisms include the interactive effects of abrupt bio-
See page 720
hemical and metabolic alterations provoked by reperfusion,
pecifically, inflammation, calcium overload, oxidative
tress, the rapid restoration of normal pH, and mitochon-
rial re-energization. The second form of reperfusion injury
s that of no-reflow or microvascular obstruction (MVO).
his describes the further disruption upon reperfusion of
he microvascular architecture, already subjected to
schemia-induced endothelial injury. With reintroduction of
picardial flow, there is additional endothelial disruption
nd capillary plugging by inflammatory cells and micro-
hrombi due to activation of inflammatory pathways, reac-
ive oxygen species, and the complement system. That limits
dequate tissue perfusion distally.
In animal models, lethal reperfusion injury accounts for
p to 50% of the final infarct size (3,4). One report
nvolving serial cardiac magnetic resonance imaging (CMR)
ith late gadolinium enhancement (LGE) suggests ongoing
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eceived research grant support from GE Healthcare Technologies.yocardial injury up to 48 h post-reperfusion with increases
n total infarct size and MVO (5). Multiple agents have
uccessfully limited infarct size when delivered just before or
t the time of reperfusion (3,4). Despite promising experi-
ental data, confirmation of therapeutic efficacy of a reper-
usion adjunct in human clinical trials continues to be
lusive, as demonstrated by the results of the phase II trial,
he F.I.R.E. (Efficacy of FX06 in the Prevention of Myo-
ardial Reperfusion Injury) study, using FX-06, reported in
his issue of the Journal (6). FX06 is an anti-inflammatory
brin derivative that competes with fibrin fragments for
inding with the vascular endothelial molecule VE-
adherin, deterring transmigration of leukocytes across the
ndothelial cell monolayer from the bloodstream into the
nfarcted tissue. It could thus theoretically reduce both
ethal reperfusion injury and no-reflow/MVO. In this mul-
icenter trial involving 26 European sites, 234 patients (of
52 screened) with first ST-segment elevation myocardial
nfarction (STEMI) were randomly assigned to either
lacebo or FX-06 given in 2 intravenous boluses at the time
f percutaneous coronary intervention (PCI). The pre-
pecified primary end point of total infarct size, as measured
y CMR-LGE, was not different between the 2 groups.
owever, the authors report a significant reduction in the
econdary end point of the “necrotic core zone” as well as
ncouraging results with regard to the safety and tolerability
f FX-06.
Is the F.I.R.E. study just another disappointing example
n a long list of failed adjunctive therapies for reperfused
I, or can we learn from its design? A notable strength is
he use of CMR-LGE, which accurately indexes the region
f irreversible myocardial injury. In fact, it is the first
ublished multicenter trial of a therapeutic reperfusion
gent that implements CMR-LGE to quantify the primary
nd point. While the nuclear technique of single-photon
mission computed tomography (SPECT) is an established
ethod for infarct quantification, the higher spatial resolu-
ion of CMR-LGE allows increased sensitivity for infarct
etection, particularly of subendocardial infarcts (7). Infarct
ize by CMR-LGE also has higher reproducibility than
PECT, allowing a potential sample size reduction to 42%
f that required for SPECT (8). This is advantageous, even
hen considering the relatively high dropout rates in the
.I.R.E. study: 87% of those eligible completed CMR-
GE at 5 days post-MI whereas only 74% underwent
ollow-up CMR at 4 months. These are likely realistic rates
nd are certainly comparable to those expected for nuclear
maging. They do, however, have to be factored into sample
ize calculations or else one risks loss of statistical power to
etect group differences, particularly at later time points, as
as observed with the F.I.R.E. study.
While it is encouraging that a CMR-LGE study was
uccessfully executed in a multitude of centers with varying
MR expertise, using scanners from all major vendors, it is
ritical that emphasis be placed on methodology to ensure
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ion and interpretation. It is particularly critical to provide
pecific details on how total infarct size, MVO, and necrotic
ore regions were defined. Prior studies in which the
ecrotic core zone was differentiated from the infarct
eriphery used the semiautomatic criterion of full-width
ne-half maximum with high reproducibility (9,10). If
ubjective planimetry of the regions of interest is proposed
nstead, as was presumably done in the F.I.R.E trial, it is
nsufficient to only report the variability in the identification
f myocardial CMR-LGE areas (i.e., presence or absence).
ather, in-depth reproducibility of the actual infarct size
uantification results (including MVO and necrotic core
egions) are required. Additionally, the use of the nonstand-
rd, relatively high 0.25 mmol/kg gadolinium dosing for
GE (11) has disadvantages, the risks of nephrogenic
clerosing fibrosis notwithstanding. The brighter blood pool
ay cause underdetection of subendocardial infarcts.
igher gadolinium dosing may also lead to underestimation
f MVO, particularly as MVO was measured relatively late
fter contrast administration, allowing ample time for con-
rast diffusion into the true no-reflow region.
Several other advantages of CMR could be exploited in
uture studies. Myocardial edema is a hallmark of even tran-
ient periods of ischemia that impair the sodium-potassium-
denosine triphosphatase pump function, allowing intracellular
odium accumulation. The T2-weighted CMR sequences are
ltrasensitive to water-bound protons and can distinguish acute
rom chronic MI (12). Recently, the T2-weighted technique
as demonstrated high accuracy in measuring the area at risk in
eperfused infarcts (13,14) and has been applied to patients
14). This technique allows the direct quantification of myo-
ardial salvage, which is a better indicator of therapeutic
fficacy in MI trials, given the strong influences of collateral
ow and area of risk on final infarct size. Furthermore, serial
maging to assess changes in T2 region, MVO, necrotic core,
nd total infarct size could be quite powerful to better under-
tand the pathophysiology and document the extent and time
ourse of human reperfusion injury. Serial imaging expands the
otential appeal of CMR-LGE as a clinical trial tool since
oth reversible and irreversible injury can be potentially quan-
ified in a single examination post-revascularization and
racked serially over time.
In summary, to determine the efficacy of adjunctive
eperfusion therapy in humans, judicious selection and
efinition of end points are paramount. For phase II clinical
rials, it is most logical to select the efficacy end point of
nfarct size, and CMR-LGE is particularly effective for
ubstantiating the existence and quantifying the extent of
eperfusion injury and verifying persistent therapeutic ben-
fits. While it is important pathophysiologically to docu-
ent acute decreases in infarct size and MVO, an agent
K
ihould demonstrate sustained, long-term infarct size reduc-
ion to be a plausible therapeutic candidate. With an
ncreased incorporation of CMR to measure end points in
linical infarct trials, one may be better able to gauge the
uccess of cardioprotective strategies in patients.
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